Biogen

News

Dangerous inflammation prompts worldwide withdrawal of MS dr...

Biogen and AbbVie have announced the voluntary withdrawal of their multiple sclerosis drug Zinbryta from all markets worldwide following dangerous brain inflammation in seven patients in Eu

News

Closeup of X-ray photography of human brain

Concerns mount over Biogen Alzheimer's drug

FDA announces guidance to encourage development of new drugs

News

Boehringer latest to axe Alzheimer's drug

Company will trial BI 409306 in schizophrenia instead.

News

Tysabri failure in stroke a setback for Biogen

Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed.

News

Roche's MS drug Ocrevus priced in line with Novartis rival i...

Drug likely to cost just under £10,000 per six-monthly injection.

News

Roche's Ocrevus MS drug approved in EU

Already a big hit in the US, Ocrevus set to make debut in EU.

Dangerous inflammation prompts worldwide withdrawal of MS dr...

Concerns mount over Biogen Alzheimer's drug

Boehringer latest to axe Alzheimer's drug

Tysabri failure in stroke a setback for Biogen

Roche's MS drug Ocrevus priced in line with Novartis rival i...

Roche's Ocrevus MS drug approved in EU

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Biogen

Editor's Picks